Ostiral (Raloxifene Hydrochloride)

Raloxifene hydrochloride, the active ingredient in Ostiral, is a selective estrogen receptor modulator (SERM) presented as a tablet for oral use. It is indicated for the treatment and prevention of osteoporosis in postmenopausal women. GNH USA supplies Ostiral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Ostiral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ostiral (raloxifene) is a SERM that acts on bone metabolism and estrogen receptors to improve skeletal health.

- Post‑menopausal osteoporosis: reduces risk of vertebral fractures and increases bone mineral density. - Prevention of osteoporosis in high‑risk post‑menopausal women: helps maintain bone strength and reduces fracture incidence. - Treatment of osteoporosis in men with primary or hypogonadal osteoporosis: improves bone density and lowers fracture risk.

Adverse reactions to raloxifene are generally mild to moderate and reflect its estrogen‑modulating activity.

Common Side Effects: - Hot flashes - Leg cramps or muscle aches - Swelling of the hands or feet - Nausea or mild gastrointestinal discomfort - Vaginal dryness or discharge

Serious or Rare Side Effects: - Deep‑vein thrombosis or pulmonary embolism - Stroke or transient ischemic attack - Severe allergic reaction (anaphylaxis) - Liver function abnormalities - Sudden vision loss or retinal artery occlusion

When using Ostiral, patients and clinicians should consider several safety aspects.

- Cardiovascular risk assessment: evaluate history of thromboembolic events before initiating therapy. - Bone health monitoring: periodic bone mineral density testing is recommended. - Menopausal symptom review: discuss potential hot‑flashes and leg cramps. - Drug interaction check: review concurrent use of anticoagulants or estrogen‑containing products. - Pregnancy and lactation: contraindicated in pregnant or breastfeeding women. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Raloxifene may interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Hormone replacement therapy or estrogen‑containing products: antagonistic effect on raloxifene’s bone benefits. - CYP3A4 inhibitors (strong): may raise raloxifene plasma levels.

Moderate Interactions (Monitor Closely): - Lipid‑lowering agents (statins): potential alteration of lipid profile monitoring. - Antidiabetic medications: possible effect on glycemic control. - NSAIDs: may increase risk of peripheral edema.